The manufacturer of Prevymis is Merck & Co., Inc. [1]
Who else makes antiviral medications?
Merck & Co., Inc. also manufactures other antiviral medications, including those for influenza. [2]
When was Prevymis approved?
Prevymis received FDA approval in November 2017. [1]
What is Prevymis used for?
Prevymis is an antiviral medication used for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult patients who are CMV-seropositive and are recipients of an allogeneic hematopoietic stem cell transplant. [1]
How does Prevymis work?
Prevymis is a ponomivircin, which is a novel antiviral agent. It inhibits the CMV DNA terminase complex. [1]
What are the potential side effects of Prevymis?
The most common side effects reported in clinical trials included diarrhea, nausea, vomiting, and abdominal pain. [1]
How long is the treatment course for Prevymis?
The recommended treatment duration for Prevymis is typically 14 weeks post-transplant. [1]
Are there any alternatives to Prevymis for CMV prophylaxis?
Other medications used for CMV prophylaxis in transplant recipients include ganciclovir and valganciclovir. However, Prevymis offers a different mechanism of action and dosing schedule. [3]
What is the patent status of Prevymis?
Information regarding specific patent filings and expiry dates for Prevymis can be found on DrugPatentWatch.com. [4]
Where can I find more detailed information on Prevymis?
More in-depth information, including prescribing information and clinical trial data, is available from the manufacturer and regulatory agencies. [1]
What is the price of Prevymis?
Pricing information for Prevymis is generally available through pharmacy benefit managers and drug pricing databases, and can vary based on insurance coverage and pharmacy. [5]
What clinical data supports Prevymis's efficacy?
Clinical trials demonstrated that Prevymis was effective in reducing the incidence of CMV infection and disease in the relevant patient population. [1]
---
Sources:
[1] https://www.merck.com/
[2] https://www.merck.com/our-responsibilities/health-equity/access-to-medicines/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1909307
[4] https://www.drugpatentwatch.com/
[5] https://www.prevymis.com/